CLINICAL, IMMUNOLOGICAL AND EPIDEMIOLOGICAL FEATURES OF HIV INFECTION IN DEPENDENCE ON HIV-1 TROPISM
https://doi.org/10.22328/2077-9828-2015-7-1-52-59
Abstract
About the Authors
N. V. MatsiyeuskayaRussian Federation
D. E. Kireev
Russian Federation
M. Y. Dmitryukova
Russian Federation
I. O. Tokunova
Russian Federation
I. A. Kpndratovich
Russian Federation
References
1. Levy J.A. HIV pathogenesis: 25 years of progress and persistent challenges // AIDS. - 2009. - Vol. 23. - Р. 147-160.
2. Mosier D.E. How HIV changes its tropism: evolution and adaptation? // Curr Opin HIV AIDS. - 2009. - Vol. 4 (2). - Р. 125-130.
3. Chikere K., Chou T., Gorry P.R., Lee B. Affinofile profiling: how efficiency of CD4/CCR5 usage impacts the biological and pathogenic phenotype of HIV // Virology. - 2013. - Vol. 435(1). - Р. 81-91.
4. Bozek K., Thielen A., Sierra S., Kaiser R., Lenqauer T. V3 Loop Sequence Space Analysis Suggests Different Evolutionary Patterns of CCR5-and CXCR4-Tropic HIV // PLoS One. - 2009. - Vol. 4(10). - Р.7387.
5. Swenson L.C., Mo T., Dong W.W., Zhong X., Woods C.K., Jensen M.A. Deep Sequencing to Infer HIV-1 Co-Receptor Usage: Application to Three Clinical Trials of Maraviroc in Treatment-Experienced Patients // J Infect Dis, 2011. - Vol. 203 (2). - Р. 237-245.
6. Матиевская Н.В., Цыркунов В.М., Гасич Е.Л., Еремин В.Ф., Козел Л.Г. Генотипы ВГС и субтипы ВИЧ у пациентов с коинфекцией ВИЧ/ВГС в Гродненском регионе Республики Беларусь // Медицинская панорама. - 2013. - Т. 1. - Р. С. 9-15.
7. Gulick R.M., Lalezari J., Goodrich J., Clumeck N., DeJesus E., Horban A. Maraviroc for Previously Treated Patients with R5 HIV-1 Infection // N Engl J Med. - 2008. - Vol. 359(14). - Р. 1429-1441.
8. Fatkenheuer G., Nelson M., Lazzarin A., Konourina I., Hoepelman A.I., Lampiris H. Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection // N Engl J Med, 2008. - Vol. 359(14). - Р.1442-1455.
9. Fuse S., Molloy M.J., Usherwood E.J. Immune Responses Against Persistent Viral Infections: Possible Avenues for Immunotherapeutic Interventions // Crit Rev Immunol. - 2008. - Vol. 28 (2). - Р. 159-183.
10. Orendi J.M., Bloem A.C., Borleffs J.C., Wijnholds F.J., de Vos N.M., Nottet H.S. Activation and Cell Cycle Antigens in CD4+ and CD8+ T Cells Correlate with Plasma Human Immunodeficiency Virus (HIV-1) RNA Level in HIV-1 Infection // J Infect Dis. - 1998. - Vol. 178 (5). - Р. 1279-1287.
11. Matsiyeuskaya N., Tsyrkunov V. Activation of blood T-cells in HIV/HCV co-infected patient // Sanamed. - 2013. - Vol. 8(1). - Р. 11-18.
12. Matsiyeuskaya, N.V., Tsyrukov V.M., Hancharou A.Y. CXCR4+ and CCR5+ expression on blood lymphocytes and its changes in AIDS development in HIV/HCV coinfected patients // Progress Health Sciences. - 2012. - Vol. 2 (2). - Р. 12-20.
13. Kinter A., McNally J., Riggin L., Jackson R., Roby G., Fauci A.S. Suppression of HIV-specific T cell activity by lymph node CD25+ regulatory T cells from HIV-infected individuals // Proc Natl Acad Sci USA. - 2007. - Vol. 104 (9). - Р. 3390-3395.
14. Ji J., Cloyd M.W. HIV-1 binding to CD4 on CD4/CD25 regulatory T cells enhances their suppressive function and induces them to home to, and accumulate in, peripheral and mucosal lymphoid tissues: an additional mechanism of immunosuppression // Int Immunol, 2009. - Vol. 21 (3). - Р. 283-294.
15. Contento R.L., Molon B., Boularan C., Pozzan T., Manes S., Marullo S., Viola A. CXCR4-CCR5: A couple modulating T cell functions // Proc Natl Acad Sci USA, 2008. - Vol. 105(29). - Р. 10101-10106.
16. Moncunill G., Armand-Ugon M., Pauls E., Clotetand B., Clotet B., Este J.A. HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro // AIDS. - 2008. - Vol. 22 (1). - Р. 23-31.
Review
For citations:
Matsiyeuskaya N.V., Kireev D.E., Dmitryukova M.Y., Tokunova I.O., Kpndratovich I.A. CLINICAL, IMMUNOLOGICAL AND EPIDEMIOLOGICAL FEATURES OF HIV INFECTION IN DEPENDENCE ON HIV-1 TROPISM. HIV Infection and Immunosuppressive Disorders. 2015;7(1):52-59. (In Russ.) https://doi.org/10.22328/2077-9828-2015-7-1-52-59